Corium, a biopharmaceutical frontrunner in the neuroscience arena, and Lotus Pharmaceutical, a global pharmaceutical powerhouse, have declared a collaboration and license agreement. This pact centers around ADLARITY (donepezil transdermal system), an unprecedented Alzheimer’s dementia therapy, targeting ten key Asian markets. ADLARITY, hailed as the U.S. Food and Drug Administration’s first-ever once-weekly patch to address mild […]
Eli Lilly and Company (Lilly) revealed complete results from its Phase 3 TRAILBLAZER-ALZ 2 study at the 2023 Alzheimer’s Association International Conference (AAIC), indicating that the experimental drug, donanemab, significantly slowed the cognitive and functional decline in patients with early symptomatic Alzheimer’s disease. The data was simultaneously published in the Journal of the American Medical […]
Quanterix, a biomarker detection firm powering scientific research and breakthrough diagnostics, has introduced LucentAD, a new test designed to aid in the evaluation of patients exhibiting cognitive symptoms indicative of early Alzheimer’s disease (AD). This test allows healthcare providers to quickly assess the likelihood of a patient exhibiting amyloid pathology, a significant marker of Alzheimer’s […]
Roche is teaming up with Eli Lilly and Company (Lilly) to support the development of its Elecsys Amyloid Plasma Panel (EAPP) blood test which has been designed by the former to enable the earlier diagnosis of Alzheimer’s disease. According to Roche, to deal with the strain that Alzheimer’s disease has on healthcare systems, it is […]
Eisai and Biogen have secured the approval of the US Food and Drug Administration (FDA) for their jointly developed Leqembi (lecanemab-irmb) under the accelerated approval pathway for the treatment of Alzheimer’s disease. Leqembi is a 100 mg/mL injection for intravenous use, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble (protofibril) and […]
Suven Life Sciences has started a global phase 3 clinical trial of Masupirdine in dementia of the Alzheimer’s type by randomizing the first patient. According to the Indian biopharma company, the late-stage trial of the serotonin-6 (5-HT6) receptor antagonist is a double-blind, placebo-controlled study intended to be held in 50 sites in North America and […]
Suven Life Sciences is set to launch a phase 3 clinical trial for its 5-HT6 antagonist SUVN-502 (Masupirdine) for the treatment of agitation and aggression in Alzheimer’s type dementias. The Indian biopharma company expects to enroll patients from mid-September. Masupirdine is a selective, brain penetrant and orally active, chemical entity. Its late-stage study to be […]
PostEra, a UK-based biotech company, has entered into a collaboration with NeuroLucent, a US company focused on developing drugs for the treatment of Alzheimer’s disease and other dementias. NeuroLucent is currently developing novel small molecule compounds that normalize a key calcium channel that is dysregulated in Alzheimer’s disease’s neurons and restore normal neuronal function in […]
PostEra, a UK-based biotech company, has entered into a collaboration with NeuroLucent, a US company focused on developing drugs for the treatment of Alzheimer’s disease and other dementias. NeuroLucent is currently developing novel small molecule compounds that normalize a key calcium channel that is dysregulated in Alzheimer’s disease’s neurons and restore normal neuronal function in […]
Belgian pharma company UCB has signed a global exclusive license deal worth up to $2 billion for its Alzheimer’s Disease drug candidate (AD drug candidate) UCB0107 with Roche and its subsidiary Genentech. UCB0107 is a monoclonal antibody drug candidate, which is being developed by UCB as a potential therapy for patients with progressive supranuclear palsy […]
